{"nctId":"NCT01997411","briefTitle":"Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes","startDateStruct":{"date":"2013-11"},"conditions":["Diabetes Mellitus, Type 1"],"count":48,"armGroups":[{"label":"Nasal Glucagon (NG)","type":"EXPERIMENTAL","interventionNames":["Drug: Nasal Glucagon"]},{"label":"Intramuscular (IM) Glucagon","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Intramuscular Glucagon"]}],"interventions":[{"name":"Nasal Glucagon","otherNames":["AMG504-1","LY900018"]},{"name":"Intramuscular Glucagon","otherNames":["GlucaGen HypoKit"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nTo be eligible, the following inclusion criteria were met:\n\n* History of type 1 diabetes and receiving daily insulin therapy from the time of diagnosis for at least 12 months\n* At least 4 years of age and less than 17 years\n* Females must have met one of the following criteria:\n\n  * Of childbearing potential but agreed to use an accepted contraceptive regimen as described in the study procedure manual throughout the entire duration of the study (from screening until study completion)\n  * Of non-childbearing potential, defined as a female who had a hysterectomy or tubal ligation, was clinically considered infertile or had not yet reached menarche\n* In good general health with no conditions that could have influenced the outcome of the trial, and in the judgment of the Investigator was a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations\n* Willingness to adhere to the study requirements\n\nExclusion Criteria:\n\nAn individual was not eligible if any of the following exclusion criteria were present:\n\n* Females who were pregnant according to a positive urine pregnancy test, actively attempting to get pregnant, or were lactating\n* History of hypersensitivity to glucagon or any related products or severe hypersensitivity reactions (such as angioedema) to any drugs\n* Presence of cardiovascular, gastrointestinal, liver or kidney disease, or any other conditions which in the judgment of the investigator could have interfered with the absorption, distribution, metabolism or excretion of drugs or could potentiate or predispose to undesired effects\n* History of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma\n* History of an episode of severe hypoglycemia (as defined by an episode that required third party assistance for treatment) in the 1 month prior to enrolling in the study\n* Use of daily systemic beta-blocker, indomethacin, warfarin or anticholinergic drugs\n* History of epilepsy or seizure disorder\n* Use of an Investigational Product in another clinical trial within the past 30 days\n* Blood donation in 3 months prior to first glucagon dosing","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Change From Baseline Concentration (Cmax) of Glucagon","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6290.33","spread":"2045.96"},{"groupId":"OG001","value":"3463.55","spread":"1760.28"},{"groupId":"OG002","value":"3958.58","spread":"2438.60"},{"groupId":"OG003","value":"4743.00","spread":"3094.61"},{"groupId":"OG004","value":"2776.27","spread":"979.28"},{"groupId":"OG005","value":"5664.33","spread":"2114.69"},{"groupId":"OG006","value":"4277.25","spread":"3774.77"},{"groupId":"OG007","value":"3103.25","spread":"2302.61"}]}]}]},{"type":"PRIMARY","title":"Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":null},{"groupId":"OG001","value":"0.25","spread":null},{"groupId":"OG002","value":"0.29","spread":null},{"groupId":"OG003","value":"0.29","spread":null},{"groupId":"OG004","value":"0.25","spread":null},{"groupId":"OG005","value":"0.25","spread":null},{"groupId":"OG006","value":"0.29","spread":null},{"groupId":"OG007","value":"0.33","spread":null}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve (AUC0-1.5) of Baseline Adjusted Glucagon","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4078.68","spread":"2078.89"},{"groupId":"OG001","value":"1744.36","spread":"978.81"},{"groupId":"OG002","value":"2472.40","spread":"1435.45"},{"groupId":"OG003","value":"3635.77","spread":"2069.11"},{"groupId":"OG004","value":"1506.23","spread":"541.57"},{"groupId":"OG005","value":"2939.31","spread":"1042.03"},{"groupId":"OG006","value":"3110.22","spread":"2848.75"},{"groupId":"OG007","value":"1999.69","spread":"1329.44"}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration (Cmax) of Baseline-Adjusted Glucose","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138.17","spread":"26.57"},{"groupId":"OG001","value":"118.18","spread":"46.46"},{"groupId":"OG002","value":"137.50","spread":"42.14"},{"groupId":"OG003","value":"130.50","spread":"21.81"},{"groupId":"OG004","value":"125.09","spread":"23.81"},{"groupId":"OG005","value":"132.82","spread":"30.59"},{"groupId":"OG006","value":"123.17","spread":"29.58"},{"groupId":"OG007","value":"102.33","spread":"25.63"}]}]}]},{"type":"PRIMARY","title":"Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"0.67","spread":null},{"groupId":"OG002","value":"1.00","spread":null},{"groupId":"OG003","value":"1.50","spread":null},{"groupId":"OG004","value":"1.00","spread":null},{"groupId":"OG005","value":"1.00","spread":null},{"groupId":"OG006","value":"1.00","spread":null},{"groupId":"OG007","value":"1.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145.86","spread":"26.94"},{"groupId":"OG001","value":"118.82","spread":"60.73"},{"groupId":"OG002","value":"142.38","spread":"51.98"},{"groupId":"OG003","value":"132.42","spread":"22.14"},{"groupId":"OG004","value":"128.82","spread":"28.45"},{"groupId":"OG005","value":"138.12","spread":"35.24"},{"groupId":"OG006","value":"126.94","spread":"30.40"},{"groupId":"OG007","value":"101.46","spread":"27.38"}]}]}]},{"type":"SECONDARY","title":"Nasal and Non-nasal Effects/Symptoms","description":"Symptoms of runny nose, nasal congestion and/or itching, sneezing, watery and/or itchy eyes, redness of eyes, and itching of ears and/or throat were assessed prior to administering glucagon and at 15, 30, 60 and 90 minutes following administration of glucagon. This was done via the \"Nasal Non-nasal Score Questionnaire\". Each of the 9 symptoms is assigned an integer value from 0 to 3; higher values indicate more severe symptoms (a score of 0 indicates no symptoms). The reported results indicate the cohort median out of a possible maximum value of 27 (summing all 9 questions for each participant and reporting the median/IQR across participants).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"0.00","spread":null},{"groupId":"OG003","value":"0.00","spread":null},{"groupId":"OG004","value":"0.00","spread":null},{"groupId":"OG005","value":"0.00","spread":null},{"groupId":"OG006","value":"0.00","spread":null},{"groupId":"OG007","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"1.00","spread":null},{"groupId":"OG002","value":"0.50","spread":null},{"groupId":"OG003","value":"0.00","spread":null},{"groupId":"OG004","value":"3.00","spread":null},{"groupId":"OG005","value":"3.00","spread":null},{"groupId":"OG006","value":"0.00","spread":null},{"groupId":"OG007","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"1.00","spread":null},{"groupId":"OG002","value":"0.50","spread":null},{"groupId":"OG003","value":"0.00","spread":null},{"groupId":"OG004","value":"2.00","spread":null},{"groupId":"OG005","value":"2.50","spread":null},{"groupId":"OG006","value":"0.00","spread":null},{"groupId":"OG007","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.50","spread":null},{"groupId":"OG002","value":"0.00","spread":null},{"groupId":"OG003","value":"0.00","spread":null},{"groupId":"OG004","value":"0.00","spread":null},{"groupId":"OG005","value":"0.50","spread":null},{"groupId":"OG006","value":"0.00","spread":null},{"groupId":"OG007","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"0.00","spread":null},{"groupId":"OG003","value":"0.00","spread":null},{"groupId":"OG004","value":"0.00","spread":null},{"groupId":"OG005","value":"0.00","spread":null},{"groupId":"OG006","value":"0.00","spread":null},{"groupId":"OG007","value":"1.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving at Least a 25 mg/dL Rise in Blood Glucose Above Nadir Level Within 30 Minutes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"11","spread":null},{"groupId":"OG005","value":"12","spread":null},{"groupId":"OG006","value":"12","spread":null},{"groupId":"OG007","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Achieving â‰¥25 mg/dL Rise in Plasma Glucose Above Nadir Level Within 30 Minutes","description":"Time (in minutes) when all participants experienced a rise in glucose \\>=25mg/dL. This is an absolute number and is not a calculated statistic. There is no distribution per cohort.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"20","spread":null},{"groupId":"OG004","value":"20","spread":null},{"groupId":"OG005","value":"15","spread":null},{"groupId":"OG006","value":"20","spread":null},{"groupId":"OG007","value":"20","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With >= 25 mg/dL Rise in Plasma Glucose Within 30 Minutes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"100","spread":null},{"groupId":"OG007","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":6},"commonTop":["Vomiting","Nausea","Headache","Injection site discomfort","Abdominal pain"]}}}